Do prolactinomas influence vessel growth.

1. Patients (both women and men) with active micro- or macroprolactinoma and prolactin levels > 40 ng/ml not on prolactin lowering therapy;

or

2. Patients (both women and men) with microprolactinoma currently treated with prolactin lowering therapy;

3. Age 18-60 years;

4. Written informed consent.

1. Retinal disease;

2. Macroprolactinemia;

3. Infundibulum infiltration;

4. Diabetes mellitus type 2;

5. Pregnant women;

6. Premature atherosclerosis;

7. Use of antidepressive and antipsychotic medication;

8. Presence of co-morbidity that could affect retinal vasculature or its matrix;

9. History of hypersensitivity or allergy to fluorescein;

10. Inability to obtain SDF, fluorescein angiograms or OCT’s of sufficient quality to be analyzed and graded;

11. Systemic disease with a life expectancy shorter than the duration of the study;

12. Active malignancy;

13. Inability to adhere to the protocol with regard to injection and follow-up visits;

14. Legally incompetent adult;

15. Refusal to give written informed consent;

16. Additional use of medication that could affect neo-angiogenesis.